Gwenn Hansen - 03 Jan 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
Issuer symbol
NRIX
Transactions as of
03 Jan 2022
Net transactions value
-$36,369
Form type
4
Filing time
04 Jan 2022, 15:19:57 UTC
Previous filing
02 Dec 2021
Next filing
21 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $2,904 +400 +2.8% $7.26 14,597 03 Jan 2022 Direct F1
transaction NRIX Common Stock Options Exercise $13,666 +1,428 +9.8% $9.57 16,025 03 Jan 2022 Direct F1
transaction NRIX Common Stock Sale $52,939 -1,828 -11% $28.96 14,197 03 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -400 -0.59% $0.000000 67,466 03 Jan 2022 Common Stock 400 $7.26 Direct F1, F2
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -1,428 -1.7% $0.000000 81,905 03 Jan 2022 Common Stock 1,428 $9.57 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
F3 The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.